Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044542 | 0.86 | MAOB (0.50) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4909799 | 0.82 | MAOB (0.49) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16000138 | 0.82 | MAOB (0.51) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27451409 | 0.79 | MAOB (0.43) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20171129 | 0.77 | HPGD (0.54) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8907080 | 0.77 | MAOB (0.41) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8907076 | 0.77 | MAOB (0.41) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2800254 | 0.76 | CYP3A4 (0.53) | SMN1; SMN2ALDH1A1TDP1L3MBTL1KMT2A | |
| SCHEMBL15997018 | 0.76 | MTNR1A (0.41) | MAOBMAOASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3571979 | 0.76 | LIPE (0.39) | MAOBSMN1; SMN2ALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785080-B | Uracil parent nucleus compound and preparation method and application thereof | 陕西盘龙药业集团股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-118652422-A | High-purity high-temperature-resistant anti-aging low-dielectric polyphenyl ether and preparation method thereof | 四川大学 | 2024-09-17 | — | — | CN | disclosed |
| CN-118164855-A | Preparation method of dibenzyl carbonate compound | 中国石油化工股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-112209838-B | Preparation method of butenaphthol hydrochloride | 鲁南制药集团股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-113135977-B | Tripterine-1, 2, 3-triazole derivative and preparation method and application thereof | 沈阳药科大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-113135977-A | Tripterine-1, 2, 3-triazole derivative and preparation method and application thereof | 沈阳药科大学 | 2021-07-20 | — | — | CN | disclosed |
| CN-112209838-A | Preparation method of butenaphthol hydrochloride | 鲁南制药集团股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-6586633-B1 | Antifungal agents | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| CN-1117960-A | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | CN | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | MAOB 1688/4885MAOA 2278/4885NPC1 1475/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | MAOB 418/4885MAOA 184/4885NPC1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.